ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Vancouver, Canada-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol DNAI. ProNAi Therapeutics initially filed confidentially on 4/8/2015. Jefferies and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
